Guilhem Richard

Guilhem Richard is a partner in Goodwin’s Life Sciences and Technology groups.

He specializes in capital markets and corporate finance particularly in the biotech, medtech and tech sectors. His experience includes a wide range of capital market transactions on Euronext and Nasdaq from equity (IPOs, dual listings, capital increases, private placements, block sales and ATM offerings…) to debt (high yield, OCEANE, ORA).

Guilhem also assists listed companies and their boards with their financing strategies and day-to-day issues relating to corporate and securities law and corporate governance.

Prior to joining Goodwin, Guilhem was a partner at Gide and previously worked in other international law firms.

Guilhem is recognized as a leader in his field by International and French preeminent, peer-reviewed publications.

• He was recently ranked in Band 4 in Capital Markets: Equity in the last edition of the Chambers France
• Ranked in Up and Coming in Capital Markets: Equity in the last edition of the Chambers Europe and Chambers Global guides
• Top Ranked Next Generation Partner in Capital Markets: Equity Capital Markets in the last edition of the Legal 500 EMEA guide

• Interview, “Guilhem Richard, un avocat qui veut du bien aux biotechs / Les cotations au Nasdaq n’ont plus de secret pour lui,” WanSquare, March 2023
• Co-Author (with Florent Bouyer), “Responsabilité du banquier introducteur pour rupture de la convention d'introduction en bourse,” Option Finance
• Co-Author (with Florent Bouyer), “Les émetteurs se rachètent auprès de leurs actionnaires,” Option Finance
• Co-Author (with Florent Bouyer), “Introduction en bourse et accès privilégié à l'offre : les viticulteurs champenois ont tracé le sillon,” Option Finance